Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
325 studies found for:    Open Studies | "Triplets"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Triplets"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel Cisplatin
2 Recruiting TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Intervention: Drug: TC (docetaxel/carboplatin) versus EC followed by T (epirubicin/cyclophosphamide followed by docetaxe)
3 Recruiting Cisplatin vs Paclitaxel for Triple Neg
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
4 Recruiting Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Other: Chemotherapy
5 Recruiting Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Merck 3475 Pembrolizumab;   Radiation: Intraoperative radiation therapy (IORT)
6 Not yet recruiting Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: IMMU-132 infusion is administered to participants in one arm for the study;   Drug: IMMU-132 plus Carboplatin infusion
7 Recruiting Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
Condition: Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm
Intervention: Procedure: Blood samples of 10 mL
8 Recruiting Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Interventions: Drug: Ixazomib;   Drug: Carboplatin
9 Recruiting Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)
Condition: Triple Negative Breast Neoplasms
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Anthracycline (doxorubicin);   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Paclitaxel
10 Recruiting Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Condition: Triple Negative Breast Neoplasms
Interventions: Drug: Docetaxel;   Drug: Carboplatin
11 Recruiting Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Pembrolizumab;   Drug: Cyclophosphamide
12 Recruiting Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
13 Recruiting Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Condition: Metastatic Triple Negative Breast Cancer
Intervention: Drug: Combination of Veliparib + Lapatinib
14 Recruiting Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: SAR566658 (ACT14884)
15 Recruiting Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Condition: Triple Negative Breast Cancer
Intervention: Drug: GTx-024
16 Recruiting Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial
Condition: Triple Negative Breast Neoplasms
Intervention: Drug: MSB0010718C
17 Not yet recruiting Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Drug: Selumetinib;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
18 Recruiting A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Condition: Triple Negative Breast Cancer
Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Nab-Paclitaxel;   Drug: Placebo
19 Not yet recruiting A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Triple-Negative Breast Cancer
Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Atezolizumab Placebo;   Drug: Paclitaxel
20 Recruiting A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Interventions: Drug: EndoTAG-1;   Drug: Paclitaxel;   Drug: Gemcitabine Hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.